CNS10-NPC-GDNF
Phase 1Biologic
CNS10-NPC-GDNF is one of 22 biologic programs targeting Liver. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
25 competitors in Liver
#DrugCompanyPhaseTrials
1Sunlenca
GileadApproved
Afinitor
NovartisPhase 3
Fetroja
ShionogiPhase 3
Tygacil
PPrism Pharmaceuticals
Phase 3
Xerava
TTetraphase Pharmaceuticals, Inc
Phase 3
Azactam
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Pipracil
WWyeth-Lederle Vaccines
Phase 3
Aztreonam-Avibactam
PfizerPhase 3
CAZ-AVI
PfizerPhase 3
Meropenem-Vaborbactam
MMelinta Therapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Liver1 trial
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
Active, not recruiting·—·Phase 1·NCT05306457·16 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CNS10-NPC-GDNF. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- CCedars-Sinai Medical Center